Skip to content

Cell and gene therapy

Cell and gene therapy

Multi-omics characterization of engineered cells: identity, potency, heterogeneity and genomic integrity.

5
layers of analysis
4
questions
1
program

Programs

Our programs

360 offer

Transcriptomics 360

Bulk, single-cell and spatial transcriptomics run as one program, on one design and one sample set.

  • Bulk RNA-seq in Marseille
  • Single-cell transcriptomics
  • Spatial transcriptomics
3
modalities
1
design, one sample set
1
project lead

Cell and gene therapy

The questions we take on

A designed program rather than an analysis order: which molecular layers answer the development question, which reference the construct requires, and which comparisons separate biological variation from process variation. Those are settled before sampling, not after.

  1. Does the engineered cell carry the intended edit or construct, and is the transgene expressed?

  2. Is the population homogeneous, or are distinct subpopulations emerging?

  3. Does the molecular profile associated with potency hold across batches and passages?

  4. Which features distinguish an intended biological effect from process-related change?

In your program

Across the development trajectory

Engineering, expansion, passage, process development, final product. Measuring only the final product hides changes in population composition, expression and genomic profile that occurred along the way, and those changes are usually what a comparability question turns on.

  1. 01

    Engineering

  2. 02

    Expansion

  3. 03

    Passage

  4. 04

    Process development

  5. 05

    Final product

GENXMAP designs the analytical strategy around the milestone, whether that is process development, potency assessment, comparability or tech transfer, defining the samples, layers, comparisons and validation steps before the study begins.

What the analysis covers

The reference comes first

Genomic characterization
WGS, WES and targeted sequencing at complementary levels of resolution, from broad genomic characterization to focused validation of selected variants or engineered regions.
Transcriptomic characterization
Bulk RNA-seq for construct expression and for the host-cell programs that engineering alters. Where the question is which cells carry the change rather than whether the population does, single-cell analysis, through Transcriptomics 360, resolves it.
Proteomic characterization
Label-free LC-MS/MS profiling performed on a timsTOF Pro 2, for the protein-level state of the engineered product.

Also covered

Batch and passage comparison
The same analytical framework applied across batches, passages and process conditions, which is what separates expected biological variation from an emerging subpopulation or a process-associated drift.
Multi-omics integration
DNA gives the genomic context, RNA the transcriptional state, protein the downstream phenotype, and single-cell data the cellular origin of each signal. They are integrated around the development question rather than reported as separate analyses.

Working with what you have

Data generated elsewhere often arrives without the metadata the analysis needs. We tell you what can be concluded from it before any work starts, rather than after.

The laboratory work can run in our Marseille laboratories (bulk RNA-seq, extraction and QC), with single-cell through Transcriptomics 360, or the analysis can start with data generated elsewhere. Existing WGS, WES, targeted sequencing, RNA-seq, proteomic or single-cell datasets can be analyzed on their own or integrated within the same framework.

WGS and WESTargeted sequencingRNA-seqProteomicsSingle-cell

What determines the analysis

  • 01The biological question
  • 02The study design
  • 03The available metadata
See the laboratory platforms

The deliverable

What you receive

A report written to be reviewed, challenged and reproduced

Study design, sample information, methods, tool versions, parameters, QC metrics and statistical results. Every analytical decision documented and traceable, built to be reviewed, challenged and reproduced by an independent team.

Study designSample informationMethods and tool versionsParametersQC metricsStatistical results

Practical terms

Report
PDF with a verifiable, time-stamped fingerprint
Data
Data is hosted in the EU, with backups in France, a separate space per team
Confidentiality
Mutual NDA available before any detail is shared, at no charge
AI
Models on our servers, no data sent to an external AI
Turnaround
In working days, confirmed in the quote, from GO

A project in this field?

GENXMAP will define the molecular characterization strategy around your development program